quantisnow
FeedTopReportsPricing
⌘K
Live feed
17:03:20·6d
SECFiling
Dermata Therapeutics Inc. logo

SEC Form DEFA14A filed by Dermata Therapeutics Inc.

DRMA· Dermata Therapeutics Inc.
Health Care
Original source

Companies

  • DRMA
    Dermata Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Sep 21UpdateBrookline Capital$14.00
  • Sep 14UpdateMaxim Group$9.00

Related

  • SEC1d
    Amendment: SEC Form SCHEDULE 13G/A filed by Dermata Therapeutics Inc.
  • SEC6d
    SEC Form DEF 14A filed by Dermata Therapeutics Inc.
  • NEWS21d
    Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System
  • SEC28d
    SEC Form 10-K filed by Dermata Therapeutics Inc.
  • SEC28d
    Dermata Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • NEWS28d
    Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025
  • INSIDER37d
    SVP, Regulatory Affairs Bedoya-Toro Munera Maria E bought $1,270 worth of shares (1,000 units at $1.27), increasing direct ownership by 8,333% to 1,012 units (SEC Form 4)
  • NEWS44d
    Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022